How Kevzara Differs from Actemra
Kevzara (sarilumab) and Actemra (tocilizumab) are both interleukin-6 (IL-6) receptor inhibitors used to treat rheumatoid arthritis (RA), giant cell arteritis (GCA), and cytokine release syndrome (CRS). They work similarly by blocking IL-6 signaling to reduce inflammation, but differ in molecular targets, approvals, dosing, and some efficacy profiles.[1][2]
Molecular Target Differences
Actemra targets both soluble and membrane-bound IL-6 receptors using two binding sites, providing broader blockade. Kevzara targets only the membrane-bound IL-6 receptor with a single binding site, potentially leading to less impact on soluble IL-6 levels.[1][3]
FDA Approvals and Indications
- Actemra has wider approval: RA (adults and kids 2+), systemic juvenile idiopathic arthritis (SJIA, kids 2+), polyarticular juvenile idiopathic arthritis (PJIA, kids 2+), GCA, CRS, severe COVID-19, and systemic sclerosis-associated interstitial lung disease.
- Kevzara covers RA (adults), polyarticular juvenile idiopathic arthritis (kids 1+), and CRS, but lacks approvals for SJIA, GCA, COVID-19, or lung disease.[2][4]
Dosing and Administration
Both come as subcutaneous injections or IV infusions, but regimens vary:
- Actemra subcutaneous: 162 mg weekly or every other week (weight-based).
- Kevzara subcutaneous: 200 mg every 2 weeks (or 150 mg for lower weight/BMI).
Kevzara requires less frequent dosing overall, though Actemra offers more flexibility for pediatrics.[1][2]
Efficacy in Key Trials
In RA head-to-head data, Kevzara showed slightly higher ACR20 response rates (66% vs. 62% for Actemra at week 24), but no significant overall superiority. Kevzara may edge out in rapid pain relief and physical function gains.[3][5] For CRS, both work, but Actemra has more real-world use from CAR-T experience.
Safety and Side Effects
Similar profiles—upper respiratory infections, neutropenia, elevated liver enzymes, and infection risk—but Kevzara has higher GI perforation rates (0.6% vs. 0.2%) and requires lipid monitoring. Both carry black-box warnings for infections and require TB screening.[1][2][6] No major differences in malignancy or cardiovascular risks.
Manufacturers and Pricing
Sanofi and Regeneron make Kevzara; Genentech (Roche) makes Actemra. U.S. list prices are close: ~$4,300-$5,000 per month for both, depending on dose, though insurance and patient assistance affect out-of-pocket costs.[7]
Patent Expirations
Actemra's key U.S. patents expire around 2033-2035, with biosimilars possible earlier via litigation. Kevzara's extend to 2032-2035. Check DrugPatentWatch.com for updates on challenges.[8][9]
Sources
[1] Kevzara FDA Label
[2] Actemra FDA Label
[3] NEJM Head-to-Head Trial
[4] FDA Kevzara Approvals
[5] Annals of Rheumatic Diseases Meta-Analysis
[6] Safety Comparison Review
[7] GoodRx Pricing Data
[8] DrugPatentWatch: Kevzara
[9] DrugPatentWatch: Actemra